Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
Abroad (travel likely)RecruitingPHASE2
Conditions
Follicular Lymphoma · Relapsed and Refractory Follicular Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Guangdong General Hospital, Guangzhou, Guangdong, China
Contact: Study coordinator (Wenyu Li, MD)Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,, Guangzhou, Guangdong, China
Contact: Study coordinator (Yudan Wu, MD)Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,, Guangzhou, Guangdong, China
Contact: Study coordinator (Qing qing Cai, MD)
Study leads
Qingqing Cai
Study Director
Sun Yat-Sen University Cancer Center